Brand Cialis

Tadalafil has been used in approximately 15,000 men participating in clinical trials, and more than 8 million men worldwide (primarily in the establishment of post-approval/post-marketing). The most common adverse side effects when using tadalafil are headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition to vasodilation (blood vessels to widen) and usually disappear after a few hours. Back pain and muscle aches can occur 12 to 24 hours after taking the drug and the symptom usually disappears after 48 hours. In May 2005 the Food and Drug Administration in the U.S. found that tadalafil (along with other PDE5 inhibitors) was associated with vision impairment related to NAION (anterior ischemic optic neuropathy, nonarteritic) in some patients taking these drugs outside of clinical trials. Most but not all, of these patients had underlying risk factors or vascular anatomy for the development of NAION associated with PDE5 use, including: rate of low coefficient of disk ("disk full"), over 50 years , diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. Given the small number of NAION events with regard to the use of PDE5 (less than 1 in 1 million), the large number of users of PDE5 inhibitors (millions) and the fact that this event occurs in a similar population those not taking these drugs, the FDA concluded that they were not able to draw a cause and effect. However, the label of all three PDE5 inhibitors was changed to alert doctors to a possible association. In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, should contain a prominent warning of the potential risk of sudden hearing loss due to post-marketing reporting of cases of deafness associated with the use of inhibitors of PDE5.6